In aiming to bypass CRISPR's delivery issues, one startup eyes the gene editing Spotlight
Much hype has been granted toward a cohort of CRISPR gene editing biotechs, including the eponymous startup founded by Nobel Prize winner Emmanuelle Charpentier. But one such company has stayed relatively quiet, albeit for a subtle series A emergence in November 2020.
Now, the GV-backed startup is ready for the spotlight with a new round of financing. Yes, the biotech is named Spotlight Therapeutics, and the 28-employee company wants to skirt the delivery issues ingrained in the typical CRISPR path of viral and nanoparticle transportation. The biotech will have to create its own spotlight to edge into the gene-editing space via in vivo cell-targeted delivery.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.